Luigi Scotto
YOU?
Author Swipe
View article: Validação de cenários de simulação clínica de atendimento a mulheres em situação de violência na Atenção Primária à Saúde
Validação de cenários de simulação clínica de atendimento a mulheres em situação de violência na Atenção Primária à Saúde Open
Objetivo: elaborar e validar cenários de simulação clínica para atendimento à mulheres em situação de violência no contexto da Atenção Primária a Saúde (APS). Métodos: estudo metodológico para elaboração de dois cenários para estudantes da…
View article: Contributions of clinical simulation in the care of women in situations of violence for training
Contributions of clinical simulation in the care of women in situations of violence for training Open
Objectives: to verify the contributions of clinical simulation on Primary Healthcare for intimate partner violence against women, through debriefing, from medical and nursing students’ perspective. Methods: a qualitative study, carried out…
View article: Clinical simulation on intimate partner violence in adolescent girls: contributions to health teaching
Clinical simulation on intimate partner violence in adolescent girls: contributions to health teaching Open
Objective to learn about the contributions of using clinical simulation with undergraduate health students to care for adolescent girls in situations of intimate partner violence in the context of Primary Health Care. Method a qualitative …
View article: Simulación clínica sobre violencia de pareja en mujeres adolescentes: aportaciones a la enseñanza en salud
Simulación clínica sobre violencia de pareja en mujeres adolescentes: aportaciones a la enseñanza en salud Open
Objetivo conocer las contribuciones del uso de la simulación clínica en la atención a mujeres adolescentes en situación de violencia de pareja en el contexto de la Atención Primaria de Salud. Método estudio cualitativo con 30 estudiantes d…
View article: Simulação clínica sobre violência por parceiro íntimo em mulheres adolescentes: contribuições para o ensino-saúde
Simulação clínica sobre violência por parceiro íntimo em mulheres adolescentes: contribuições para o ensino-saúde Open
Objetivo conhecer as contribuições do uso de simulação clínica, com graduandos da área da saúde, para o atendimento à mulher adolescente em situação de violência por parceiro íntimo no contexto da Atenção Primária à Saúde. Método estudo qu…
View article: Contribuições da simulação clínica no atendimento à mulher em situação de violência para formação
Contribuições da simulação clínica no atendimento à mulher em situação de violência para formação Open
RESUMO Objetivos: verificar as contribuições da simulação clínica sobre atendimento na Atenção Primária à Saúde à violência por parceiros íntimos contra mulheres, por meio de debriefing, na perspectiva dos estudantes de medicina e enfermag…
View article: “A Man Has to Show That He Is a Man From a Young Age”: Intimate Partner Violence for Young Male University Students in Brazil
“A Man Has to Show That He Is a Man From a Young Age”: Intimate Partner Violence for Young Male University Students in Brazil Open
Considering that men today face social and cultural pressures to behave in certain ways, the objective of this study was to analyze the construction of Intimate Partner Violence (IPV) from the perspective of university students who identif…
View article: Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic adenocarcinoma
Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic adenocarcinoma Open
Pancreatic ductal adenocarcinoma-(PDAC) needs innovative approaches due to its 12% 5-year survival despite current therapies. We show marked sensitivity of pancreatic cancer cells to the combination of a novel eIF4A inhibitor, des-methyl p…
View article: Novel Therapeutic Strategies Exploiting the Unique Properties of Neuroendocrine Neoplasms
Novel Therapeutic Strategies Exploiting the Unique Properties of Neuroendocrine Neoplasms Open
Background: Over the last few decades of treatment, the outcomes for at least some subsets of neuroendocrine neoplasms (NENs) have improved. However, the identification of new vulnerabilities for this heterogeneous group of cancers remains…
View article: Identifying the mechanistic differences between hypomethylating agents for the treatment of peripheral T cell lymphoma
Identifying the mechanistic differences between hypomethylating agents for the treatment of peripheral T cell lymphoma Open
Introduction: Peripheral T-cell lymphomas (PTCL) are a rare and heterogeneous group of malignancies that share a unifying feature of epigenetic dysregulation. Recent evidence suggests that PTCL, unlike other forms of cancer or even lymphom…
View article: Supplementary Data from R-Loop–Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin
Supplementary Data from R-Loop–Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin Open
Supplementary Figures 1-7 and Supplementary Table 1
View article: Data from R-Loop–Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin
Data from R-Loop–Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin Open
Histone deacetylase inhibitors (HDACi) induce hyperacetylation of histones by blocking HDAC catalytic sites. Despite regulatory approvals in hematological malignancies, limited solid tumor clinical activity has constrained their potential,…
View article: Data from R-Loop–Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin
Data from R-Loop–Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin Open
Histone deacetylase inhibitors (HDACi) induce hyperacetylation of histones by blocking HDAC catalytic sites. Despite regulatory approvals in hematological malignancies, limited solid tumor clinical activity has constrained their potential,…
View article: Supplementary Data from R-Loop–Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin
Supplementary Data from R-Loop–Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin Open
Supplementary Figures 1-7 and Supplementary Table 1
View article: Supplementary Figure Legend from Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas
Supplementary Figure Legend from Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas Open
PDF file, 43KB.
View article: Supplementary Figure 1 from Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas
Supplementary Figure 1 from Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas Open
PDF file, 432KB, PCR genotyping analysis of CD19cherryluciferase transgenic founders. PCR products of the targeted and wild type alleles of the CD19 locus in two transgenic founders. The PCR conditions for the left arm insertion were: 95{d…
View article: Supplemental Figure 1 from Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma
Supplemental Figure 1 from Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma Open
Peripheral blood mononuclear cells (PBMCs) were separated from whole blood by Ficoll-Paque layering. (A) Concentration : effect relationship was determined for ACY-1215 at 24 and 48 hours in PBMCs. No cytotoxicity was observed after 24 and…
View article: Supplementary Data from Pralatrexate Is Synergistic with the Proteasome Inhibitor Bortezomib in <i>In vitro</i> and <i>In vivo</i> Models of T-Cell Lymphoid Malignancies
Supplementary Data from Pralatrexate Is Synergistic with the Proteasome Inhibitor Bortezomib in <i>In vitro</i> and <i>In vivo</i> Models of T-Cell Lymphoid Malignancies Open
Supplementary Data from Pralatrexate Is Synergistic with the Proteasome Inhibitor Bortezomib in In vitro and In vivo Models of T-Cell Lymphoid Malignancies
View article: Supplementary Data from Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma
Supplementary Data from Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma Open
Supplementary Data from Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma
View article: Supplemental Figure 1 from Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib
Supplemental Figure 1 from Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib Open
Standard error values for ACY-1215 plus ibrutinib combinations in cell lines and primary human lymphoma samples. Viability was measured by CellTiter-Glo. Each experiment was performed in triplicate and repeated at least 2 times. The standa…
View article: Data from Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma
Data from Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma Open
Purpose: T-cell lymphomas (TCL) are aggressive diseases, which carry a poor prognosis. The emergence of new drugs for TCL has created a need to survey these agents in a rapid and reproducible fashion, to prioritize combinations whic…
View article: Supplementary Figure 1 from Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas
Supplementary Figure 1 from Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas Open
PDF file, 432KB, PCR genotyping analysis of CD19cherryluciferase transgenic founders. PCR products of the targeted and wild type alleles of the CD19 locus in two transgenic founders. The PCR conditions for the left arm insertion were: 95{d…
View article: Supplementary Figure 1 from Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma
Supplementary Figure 1 from Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma Open
Supplementary Figure 1. 0.75 nM of PDX in combination with 100 nM of alisertib was obsereved in a schedule dependent manner to evaluate drug:drug interactions. Simultaneous incubation of drugs is depicted as (I), while schedule (drug A bef…
View article: Data from Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas
Data from Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas Open
Purpose: To generate a transgenic mouse that when crossed with spontaneous mouse models of lymphoma will allow for quantitative in vivo measurement of tumor burden over the entire spectrum of the disease and or response to th…
View article: Data from Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma
Data from Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma Open
Purpose: Pan-class histone deacetylase (HDAC) inhibitors are effective treatments for select lymphomas. Isoform-selective HDAC inhibitors are emerging as potentially more targeted agents. HDAC6 is a class IIb deacetylase that facili…
View article: Data from Pralatrexate Is Synergistic with the Proteasome Inhibitor Bortezomib in <i>In vitro</i> and <i>In vivo</i> Models of T-Cell Lymphoid Malignancies
Data from Pralatrexate Is Synergistic with the Proteasome Inhibitor Bortezomib in <i>In vitro</i> and <i>In vivo</i> Models of T-Cell Lymphoid Malignancies Open
Purpose: Pralatrexate (10-propargyl-10-deazaaminopterin) is an antifolate with improved cellular uptake and retention due to greater affinity for the reduced folate carrier (RFC-1) and folyl-polyglutamyl synthase. Based on the PROPE…
View article: Data from Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma
Data from Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma Open
Purpose: Romidepsin and belinostat are inhibitors of histone deacetylases (HDACI). HDACIs are known to induce cell death in malignant cells through multiple mechanisms, including upregulation of death receptors and induction of cell…
View article: Supplementary Figure 3 from Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas
Supplementary Figure 3 from Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas Open
PDF file, 576KB, Confocal analysis of PBMC of A) wild type and B) single transgenic mice. Mature naive B cells expressing the cherry protein were observed in freshly isolated PBMC stained with a, c, e and g) DAPI, to visualize nuclei. b, d…
View article: Supplementary Figures 1-2, Supplementary Table 1 from Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma
Supplementary Figures 1-2, Supplementary Table 1 from Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma Open
Supplementary Figures 1-2, Supplementary Table 1. Supplementary Figure 1: Highthroughput Matrix For H9 and HH. Highthroughput screen was used to determine the synergistic interaction in vitro in H9 and HH T-cell lines. (A) Depicts the obse…
View article: Data from Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma
Data from Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma Open
Purpose: Romidepsin and belinostat are inhibitors of histone deacetylases (HDACI). HDACIs are known to induce cell death in malignant cells through multiple mechanisms, including upregulation of death receptors and induction of cell…